Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
ANNX similar filings
- 12 Aug 24 Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
- 5 Aug 24 Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
- 25 Jun 24 Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
- 12 Jun 24 Submission of Matters to a Vote of Security Holders
- 7 Jun 24 Annexon Announces Pricing of $125 Million Underwritten Public Offering
- 4 Jun 24 Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
- 13 May 24 Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
Filing view
External links